Hyuk Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hyuk Kim has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Jeong-Ju Yoo
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheonsi, Republic of Korea
6 shared publications - Moon Young Kim
Regeneration Medicine Research Center, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea
5 shared publications - Sang Gyune Kim
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon 14584, Republic of Korea
5 shared publications - Jae Young Kim
Department of Statistics, Soonchunhyang University Bucheon Hospital, Bucheon, Korea
2 shared publications - Yoon-E Shin
Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon 14584, Republic of Korea
2 shared publications - Bora Kim
Division of Hematology-Oncology, Department of Medicine, Soonchunhyang University, Bucheon Hospital, Bucheon, Korea
1 shared publication
Latest Publications
- Open Access
- 10 September 2026
- Published by Korean Medical Association in Journal of the Korean Medical Association
- Vol. 69 (9) , 715-726
Liver-centric strategies for immune enhancement: an evidence-based review of the gut–liver axis, metabolism, lifestyle, and vaccination
Purpose: Although the liver is widely recognized as the body’s primary metabolic organ, it also functions as a major immunometabolic interface between the gut and systemic circulation. Continuous exposure to gut-derived antigens requires a tightly regulated balance between immune tolerance and immune activation. Therefore, “immune enhancement” should be understood as optimization of the hepatic immune-metabolic network rather than nonspecific stimulation of immune responses. This review summarizes evidence-based strategies for supporting hepatic and systemic immunity in patients with chronic liver disease and in the general population.Current concepts: Hepatic immunity is regulated largely by innate immune components, including Kupffer cells, liver sinusoidal endothelial cells, and Toll-like receptor signaling. The gut–liver axis is a major pathway of immune regulation; probiotics and postbiotics may strengthen the intestinal barrier and reduce lipopolysaccharide-driven inflammation. Nutrients such as branched-chain amino acids, vitamin D, zinc, and selenium support immune-cell function and may help attenuate immunosenescence. Silymarin and melatonin may reduce oxidative stress and modulate nuclear factor κB- and transforming growth factor-β1-mediated inflammatory and fibrotic pathways. Regular moderate exercise and adequate sleep also contribute to immune regulation through anti-inflammatory myokines and circadian stabilization. In cirrhosis-associated immune dysfunction, vaccination against hepatitis A and B, pneumococcus, influenza, and coronavirus disease 2019 is essential for reducing the risk of infection and decompensation.Discussion and conclusion: Maintaining liver health is integral to systemic immune function. A liver-centered strategy that combines gut microbiome modulation, appropriate nutritional supplementation, regular exercise, adequate sleep, and vaccination is preferable to unverified “immune-boosting” supplements.
- 10 September 2026
- Published by Korean Medical Association in Journal of the Korean Medical Association
- Vol. 69 (9) , 715-726
Open AccessLiver-centric strategies for immune enhancement: an evidence-based review of the gut–liver axis, metabolism, lifestyle, and vaccination
Purpose: Although the liver is widely recognized as the body’s primary metabolic organ, it also functions as a major immunometabolic interface between the gut and systemic circulation. Continuous exposure to gut-derived antigens requires a tightly regulated balance between immune tolerance and immune activation. Therefore, “immune enhancement” should be understood as optimization of the hepatic immune-metabolic network rather than nonspecific stimulation of immune responses. This review summarizes evidence-based strategies for supporting hepatic and systemic immunity in patients with chronic liver disease and in the general population.Current concepts: Hepatic immunity is regulated largely by innate immune components, including Kupffer cells, liver sinusoidal endothelial cells, and Toll-like receptor signaling. The gut–liver axis is a major pathway of immune regulation; probiotics and postbiotics may strengthen the intestinal barrier and reduce lipopolysaccharide-driven inflammation. Nutrients such as branched-chain amino acids, vitamin D, zinc, and selenium support immune-cell function and may help attenuate immunosenescence. Silymarin and melatonin may reduce oxidative stress and modulate nuclear factor κB- and transforming growth factor-β1-mediated inflammatory and fibrotic pathways. Regular moderate exercise and adequate sleep also contribute to immune regulation through anti-inflammatory myokines and circadian stabilization. In cirrhosis-associated immune dysfunction, vaccination against hepatitis A and B, pneumococcus, influenza, and coronavirus disease 2019 is essential for reducing the risk of infection and decompensation.Discussion and conclusion: Maintaining liver health is integral to systemic immune function. A liver-centered strategy that combines gut microbiome modulation, appropriate nutritional supplementation, regular exercise, adequate sleep, and vaccination is preferable to unverified “immune-boosting” supplements.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (39)
Superior Efficacy of Besifovir in Reducing Hepatocellular Carcinoma Risk Compared to Tenofovir in Chronic Hepatitis B Patients: A Nationwide Cohort Study
Shin YE, et al. J Korean Med Sci. 2026 Oct;41:e251. https://doi.org/10.3346/jkms.2026.41.e251
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (39)
Open AccessSuperior Efficacy of Besifovir in Reducing Hepatocellular Carcinoma Risk Compared to Tenofovir in Chronic Hepatitis B Patients: A Nationwide Cohort Study
Shin YE, et al. J Korean Med Sci. 2026 Oct;41:e251. https://doi.org/10.3346/jkms.2026.41.e251
- Open Access
- 25 August 2025
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 20 (1) , 153-157
Coffee and the Risk of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Mendelian Randomization Studies
Hyun Bin Choi, Hyuk Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl250227
- 25 August 2025
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 20 (1) , 153-157
Open AccessCoffee and the Risk of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Mendelian Randomization Studies
Hyun Bin Choi, Hyuk Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl250227
- Open Access
A Potential Pneumothorax Induced by Immune Checkpoint Inhibitors: A Case Report and Literature Review
Background and Objectives: Immune checkpoint inhibitors (ICIs), which target immune checkpoints in cancer cells, are increasingly used as a mainstay in anticancer treatment. The combination of atezolizumab and bevacizumab is also a first-line treatment for hepatocellular carcinoma (HCC). However, ICIs can cause immune-related adverse events (IrAEs) which range from mild to severe, potentially leading to the need for discontinuing immunotherapy. We report a case of a pneumothorax, a rare side effect caused by IrAEs. Materials and Methods: This paper reports a case of a 78-year-old male HCC patient who developed a recurrent pneumothorax, suspected to be an adverse effect of ICIs. Results: The patient was a current smoker with a 30 pack-year smoking history. Prior to initiating ICIs, a chest CT scan showed mild emphysema and fibrosis attributable to smoking. Following ICI treatment, the patient developed a recurrent pneumothorax. Further tests revealed no underlying cause for the pneumothorax other than the ICIs and smoking, and there were no signs of intrapulmonary metastasis or pneumonitis. Conclusions: When a pneumothorax occurs in a patient undergoing immunotherapy, it is important to consider it as a potential adverse effect of the treatment. Special attention should be given to the possibility that immunotherapy may exacerbate underlying lung conditions. Patients should be advised on the importance of smoking cessation. As there are currently no guidelines for resuming immunotherapy after a pneumothorax, it is crucial to weigh the risks and benefits and consider dose reduction or discontinuation of the medication.
Open AccessA Potential Pneumothorax Induced by Immune Checkpoint Inhibitors: A Case Report and Literature Review
Background and Objectives: Immune checkpoint inhibitors (ICIs), which target immune checkpoints in cancer cells, are increasingly used as a mainstay in anticancer treatment. The combination of atezolizumab and bevacizumab is also a first-line treatment for hepatocellular carcinoma (HCC). However, ICIs can cause immune-related adverse events (IrAEs) which range from mild to severe, potentially leading to the need for discontinuing immunotherapy. We report a case of a pneumothorax, a rare side effect caused by IrAEs. Materials and Methods: This paper reports a case of a 78-year-old male HCC patient who developed a recurrent pneumothorax, suspected to be an adverse effect of ICIs. Results: The patient was a current smoker with a 30 pack-year smoking history. Prior to initiating ICIs, a chest CT scan showed mild emphysema and fibrosis attributable to smoking. Following ICI treatment, the patient developed a recurrent pneumothorax. Further tests revealed no underlying cause for the pneumothorax other than the ICIs and smoking, and there were no signs of intrapulmonary metastasis or pneumonitis. Conclusions: When a pneumothorax occurs in a patient undergoing immunotherapy, it is important to consider it as a potential adverse effect of the treatment. Special attention should be given to the possibility that immunotherapy may exacerbate underlying lung conditions. Patients should be advised on the importance of smoking cessation. As there are currently no guidelines for resuming immunotherapy after a pneumothorax, it is crucial to weigh the risks and benefits and consider dose reduction or discontinuation of the medication.
- Open Access
- 10 September 2024
- Published by Korean Medical Association in Journal of the Korean Medical Association
- Vol. 67 (9) , 603-611
Ursodeoxycholic acid in hepatobiliary diseases
Background: This study aimed to summarize evidence of ursodeoxycholic acid (UDCA) use in the management of hepatobiliary diseases, present indications for UDCA use in Korea, and reimbursement criteria for UDCA use in the country.Current Concepts: UDCA is currently approved for the treatment and prevention of gallstone in obese patients with rapid weight loss after post-bariatric surgery, primary biliary cirrhosis (PBC), chronic liver disease with markedly elevated liver function test values, and chronic hepatitis C. However, the approval and reimbursement criteria for UDCA depend on the dose, specific diseases, and circumstances. UDCA is administered at doses of 100, 200, and 300 mg. The 100 mg dose is available over-the-counter, whereas a prescription is required for the 200 and 300 mg doses. The approval standards differed by dose: UDCA 100 mg for biliary diseases and chronic liver disease; UDCA 200 mg for gallstone, PBC, and chronic hepatitis C; and UDCA 300 mg for PBC, gallstone prevention in obese patients, and patients who had undergone gastrectomy. Co-administration of UDCA with antiviral drugs may require patients to bear some costs. UDCA can be combined with either milk thistle or biphenyl dimethyl dicarboxylate but not both.Discussion and Conclusion: UDCA is a relatively safe medication with many benefits. The current reimbursement standards for hepatobiliary diseases include chronic liver disease with elevated liver enzyme levels, gallstone, PBC, chronic hepatitis B, and chronic hepatitis C. Because UDCA is administered at varied doses, it is important to know the appropriate dose and regimen for each condition.
- 10 September 2024
- Published by Korean Medical Association in Journal of the Korean Medical Association
- Vol. 67 (9) , 603-611
Open AccessUrsodeoxycholic acid in hepatobiliary diseases
Background: This study aimed to summarize evidence of ursodeoxycholic acid (UDCA) use in the management of hepatobiliary diseases, present indications for UDCA use in Korea, and reimbursement criteria for UDCA use in the country.Current Concepts: UDCA is currently approved for the treatment and prevention of gallstone in obese patients with rapid weight loss after post-bariatric surgery, primary biliary cirrhosis (PBC), chronic liver disease with markedly elevated liver function test values, and chronic hepatitis C. However, the approval and reimbursement criteria for UDCA depend on the dose, specific diseases, and circumstances. UDCA is administered at doses of 100, 200, and 300 mg. The 100 mg dose is available over-the-counter, whereas a prescription is required for the 200 and 300 mg doses. The approval standards differed by dose: UDCA 100 mg for biliary diseases and chronic liver disease; UDCA 200 mg for gallstone, PBC, and chronic hepatitis C; and UDCA 300 mg for PBC, gallstone prevention in obese patients, and patients who had undergone gastrectomy. Co-administration of UDCA with antiviral drugs may require patients to bear some costs. UDCA can be combined with either milk thistle or biphenyl dimethyl dicarboxylate but not both.Discussion and Conclusion: UDCA is a relatively safe medication with many benefits. The current reimbursement standards for hepatobiliary diseases include chronic liver disease with elevated liver enzyme levels, gallstone, PBC, chronic hepatitis B, and chronic hepatitis C. Because UDCA is administered at varied doses, it is important to know the appropriate dose and regimen for each condition.
- Open Access
Atezolizumab-Induced Ulcerative Colitis in Patient with Hepatocellular Carcinoma: Case Report and Literature Review
Background and Objectives: Immune check inhibitor (ICI) colitis is one of most common and adverse side effects of ICI. However, there was no case report of ulcerative colitis (UC)-mimicking colitis after atezolizumab use in hepatocellular carcinoma (HCC) to our knowledge. Materials and Methods: We would like to introduce the case of a patient with Stage IV HCC who complained of abdominal pain, diarrhea and rectal bleeding after two cycles of atezolizumab/bevacizumab chemotherapy and was then diagnosed with UC-mimicking colitis. Results: Endoscopy revealed typical findings of UC, suggesting diagnosis of UC-mimicking colitis. The patient was treated with systemic steroids and oral mesalamine, which significantly improved his symptoms, which were also supported by endoscopic findings. The patient resumed chemotherapy with atezolizumab and bevacizumab without any interruption to the chemotherapy schedule. Conclusions: Early endoscopic evaluation is pivotal to diagnosing UC-mimicking colitis. If diagnosed, UC-based treatments such as steroids and mesalamine should be strongly considered. Given previous reports of inflammatory bowel disease (IBD) flare-ups after immunotherapy, routine lower endoscopy, performed together with upper endoscopy before atezolizumab/bevacizumab therapy, is promising to patients.
Open AccessAtezolizumab-Induced Ulcerative Colitis in Patient with Hepatocellular Carcinoma: Case Report and Literature Review
Background and Objectives: Immune check inhibitor (ICI) colitis is one of most common and adverse side effects of ICI. However, there was no case report of ulcerative colitis (UC)-mimicking colitis after atezolizumab use in hepatocellular carcinoma (HCC) to our knowledge. Materials and Methods: We would like to introduce the case of a patient with Stage IV HCC who complained of abdominal pain, diarrhea and rectal bleeding after two cycles of atezolizumab/bevacizumab chemotherapy and was then diagnosed with UC-mimicking colitis. Results: Endoscopy revealed typical findings of UC, suggesting diagnosis of UC-mimicking colitis. The patient was treated with systemic steroids and oral mesalamine, which significantly improved his symptoms, which were also supported by endoscopic findings. The patient resumed chemotherapy with atezolizumab and bevacizumab without any interruption to the chemotherapy schedule. Conclusions: Early endoscopic evaluation is pivotal to diagnosing UC-mimicking colitis. If diagnosed, UC-based treatments such as steroids and mesalamine should be strongly considered. Given previous reports of inflammatory bowel disease (IBD) flare-ups after immunotherapy, routine lower endoscopy, performed together with upper endoscopy before atezolizumab/bevacizumab therapy, is promising to patients.